Cargando…

TERT mutations correlate with higher TMB value and unique tumor microenvironment and may be a potential biomarker for anti‐CTLA4 treatment

Immune checkpoint inhibitors (ICIs) have recently changed therapeutic paradigms for patients across multiple cancer types. However, current biomarkers cannot accurately predict responses to ICIs. Telomerase reverse transcriptase (TERT) mutations lead to an aberrant upregulation of TERT expression, a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Huahua, Li, Jia, Zhang, Chenyue, Zhang, Chenxing, Wang, Haiyong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7541140/ https://www.ncbi.nlm.nih.gov/pubmed/32810393 http://dx.doi.org/10.1002/cam4.3376

Ejemplares similares

Male patients with TERT mutation may be more likely to benefit from immunotherapy, especially for melanoma
por: Li, Jia, et al.
Publicado: (2020)

Loss of heterozygosity related to TMB and TNB may predict PFS for patients with SCLC received the first line setting
por: Zhang, Chenyue, et al.
Publicado: (2021)

Identification of a Gene Signature Closely Related to Immunosuppressive Tumour Microenvironment Predicting Prognosis of Patients in EGFR Mutant Lung Adenocarcinoma
por: Li, Jia, et al.
Publicado: (2021)

Patients With BRAF-Mutant NSCLC May Not Benefit From Immune Checkpoint Inhibitors: A Population-Based Study
por: Zhang, Chenxing, et al.
Publicado: (2020)

Genomic Variations and Immune-Related Features of TMB, PD-L1 Expression and CD8(+) T Cell Infiltration in Chinese Pulmonary Sarcomatoid Carcinoma
por: Zhang, Chenyue, et al.
Publicado: (2022)

A 5-Gene Signature Is Closely Related to Tumor Immune Microenvironment and Predicts the Prognosis of Patients with Non-Small Cell Lung Cancer
por: Li, Jia, et al.
Publicado: (2020)

Construction of immune-related and prognostic lncRNA clusters and identification of their immune and genomic alterations characteristics in lung adenocarcinoma samples
por: Li, Jia, et al.
Publicado: (2020)

Orchestrating smart therapeutics to achieve optimal treatment in small cell lung cancer: recent progress and future directions
por: Zhang, Chenyue, et al.
Publicado: (2023)

Circular RNA hsa_circ_0078602 may have potential as a prognostic biomarker for patients with hepatocellular carcinoma
por: Kou, Peisi, et al.
Publicado: (2019)

The prognostic value of TMB in early-stage non-small cell lung cancer: a systematic review and meta-analysis
por: Wankhede, Durgesh, et al.
Publicado: (2023)

Differences in Stage of Cancer at Diagnosis, Treatment, and Survival by Race and Ethnicity Among Leading Cancer Types
por: Zhang, Chenyue, et al.
Publicado: (2020)

Targeting the tumor mutanome for personalized vaccination in a TMB low non-small cell lung cancer
por: McCann, Katy, et al.
Publicado: (2022)

NTRK fusion positive colorectal cancer is a unique subset of CRC with high TMB and microsatellite instability
por: Wang, Hui, et al.
Publicado: (2022)

Human TERT promoter mutations as a prognostic biomarker in glioma
por: Powter, Branka, et al.
Publicado: (2021)

Open the Technical Black Box of Tumor Mutational Burden (TMB): Factors Affecting Harmonization and Standardization of Panel-Based TMB
por: Sung, Meng-Ta, et al.
Publicado: (2022)

Therapeutic utility of Lung-MAP: ushering into an era of genomic and biomarker-driven clinical trials
por: Zhang, Chenyue, et al.
Publicado: (2021)

Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project
por: Merino, Diana M, et al.
Publicado: (2020)

Long non-coding RNA FTX predicts a poor prognosis of human cancers: a meta-analysis
por: Chen, Weiwei, et al.
Publicado: (2021)

The Prognostic Value of ctDNA and bTMB on Immune Checkpoint Inhibitors in Human Cancer
por: Wei, Jiayan, et al.
Publicado: (2021)

TMB in NSCLC: A Broken Dream?
por: Bravaccini, Sara, et al.
Publicado: (2021)

Identifying Inconsistencies and Reporting Deficits in Therapeutic Massage and Bodywork (TMB) Case Reports Authored by TMB Practitioners: a TMB-Adapted CAse REport (CARE) Guidelines Audit Through 2014
por: Munk, Niki, et al.
Publicado: (2016)

CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations
por: Camacho, Luis H
Publicado: (2015)

Neoadjuvant chemotherapy remodels the tumor immune microenvironment by increasing activated and cytotoxic T cell, decreasing B cells and macrophages in small cell lung cancer
por: Shang, Xiaoling, et al.
Publicado: (2023)

The Greater Value of the CONSORT Statement Guidelines: Guideposts for Designing and Reporting all TMB Research
por: Porcino, Antony J.
Publicado: (2012)

The prognostic value of tumor mutation burden (TMB) and its relationship with immune infiltration in breast cancer patients
por: Cui, Shengjin, et al.
Publicado: (2023)

ctDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitors
por: Nie, Wei, et al.
Publicado: (2022)

Plasma microRNA-720 may predict prognosis and diagnosis in glioma patients
por: Chen, Peng, et al.
Publicado: (2020)

CTLA4-Mediated Immunosuppression in Glioblastoma is Associated with the Infiltration of Macrophages in the Tumor Microenvironment
por: Guan, Xiudong, et al.
Publicado: (2021)

Tissue-Plasma TMB Comparison and Plasma TMB Monitoring in Patients With Metastatic Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitors
por: Friedlaender, Alex, et al.
Publicado: (2020)

OGDHL closely associates with tumor microenvironment and can serve as a prognostic biomarker for papillary thyroid cancer
por: Mao, Min, et al.
Publicado: (2021)

Prognostic value of Ki-67 in nasopharyngeal carcinoma: a meta-analysis
por: Li, Yulin, et al.
Publicado: (2021)

Cuproptosis-related LncRNAs are correlated with immunity and predict prognosis in HNSC independent of TMB
por: Li, Mingyu, et al.
Publicado: (2023)

Assessing tumor heterogeneity: integrating tissue and circulating tumor DNA (ctDNA) analysis in the era of immuno-oncology - blood TMB is not the same as tissue TMB
por: Fridland, Stanislav, et al.
Publicado: (2021)

Implementing TMB measurement in clinical practice: considerations on assay requirements
por: Büttner, Reinhard, et al.
Publicado: (2019)

Exploring the prognostic function of TMB-related prognostic signature in patients with colon cancer
por: Zhao, Yan, et al.
Publicado: (2023)

The landscape and prognostic value of immune characteristics in uterine corpus endometrial cancer
por: Liu, Wenli, et al.
Publicado: (2021)

TMB and TCR Are Correlated Indicators Predictive of the Efficacy of Neoadjuvant Chemotherapy in Breast Cancer
por: Liang, Hongling, et al.
Publicado: (2021)

Prognostic value of tumor mutation burden (TMB) and INDEL burden (IDB) in cancer: current view and clinical applications
por: Saeed, Anwaar, et al.
Publicado: (2020)

Case Report: Two Cases of Soft-Tissue Sarcomas: High TMB as a Potential Predictive Biomarker for Anlotinib Combined With Toripalimab Therapy
por: Li, Yong, et al.
Publicado: (2022)

What makes TMB an ambivalent biomarker for immunotherapy? A subtle mismatch between the sample-based design of variant callers and real clinical cohort
por: Liu, Yuqian, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3c3nqcp61u00dajqqltqas32ek